Aspira Women`s Health Inc Stock
Aspira Women`s Health Inc Stock price
Key metrics
| Market capitalization | $2.44m |
| Enterprise Value | $2.19m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| EV/Sales (TTM) EV/Sales | 0.24 |
| P/S ratio (TTM) P/S ratio | 0.26 |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue growth (TTM) Revenue growth | 3.53% |
| Revenue (TTM) Revenue | $9.31m |
Is Aspira Women`s Health Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
Aspira Women`s Health Inc Stock Analysis
Analyst Opinions
1 Analyst has issued a forecast Aspira Women`s Health Inc:
Analyst Opinions
1 Analyst has issued a forecast Aspira Women`s Health Inc:
Financial data from Aspira Women`s Health Inc
| Mar '25 |
+/-
%
|
||
| Revenue | 9.31 9.31 |
4%
4%
|
|
| Gross Profit | 5.83 5.83 |
10%
10%
|
|
| EBITDA | -15 -15 |
14%
14%
|
EBIT (Operating Income) EBIT | -15 -15 |
14%
14%
|
| Net Profit | -10 -10 |
30%
30%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Aspira Women`s Health Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aspira Women`s Health Inc Stock News
Company Profile
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. The company serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas.
| Head office | United States |
| CEO | Michael Buhle |
| Employees | 66 |
| Founded | 1993 |
| Website | www.aspirawh.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
